TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02685787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention
Description: The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention on AD
Description: The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions.
Study: NCT03368599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscope guided advancement
Description: During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the bronchoscope-guided method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Pass the fiberoptic bronschoscope through a bronchial lumen of Lt. DLT.~3. Secure the pathway into the Lt. main bronchus by advancing the bronchoscope into the Lt. main bronchus.~4. Lt. DLT can be advanced through the guide of the bronchoscope into Lt. main bronchus.~5. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional advancement
Description: During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the conventional method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Rotate Lt. DLT 90 degrees to the left side.~3. Advance Lt. DLT blindly to main bronchus level.~4. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified.
Study: NCT02917629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02276014

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beta-carotene

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beta-carotene

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beta-carotene
Study: NCT03272464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib may work by stopping your cancer cells from duplicating.
Study: NCT02332512

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03272464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB039110
Description: Itacitinib may work by stopping your tumor cells from living and growing.
Study: NCT04361149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Topical Cream (0.075%)
Description: Capsaicin cream will be administered as a topical skin cream

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delsys Trigno Galileo System
Description: A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Delsys Trigno Galileo System
Description: A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excaliber, Natus Medical
Description: Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Excaliber, Natus Medical
Description: Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream will be administered as a topical skin cream
Study: NCT00615654

Intervention type: OTHER
Group type: OTHER
Intervention: aquatic physical therapy
Description: The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
Study: NCT01454908

Intervention type: DEVICE
Group type: OTHER
Intervention: Oxford Partial Knee
Description: The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
Study: NCT03964064

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-printing Template-assisted CT-guided I125 Seed Implantation
Description: CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
Study: NCT04059458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)
Description: Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)
Description: Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Description: Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Description: Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
Study: NCT00988442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced nursing telephone support
Description: Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Usual ACTG site care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Usual ACTG site care.
Study: NCT04509882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bear bile pill
Description: Bear bile pill (15 pills) taken orally three times a day after meals with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo(15 pills) taken orally three times a day after meals with water.
Study: NCT03174262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ergonomic Computer Workstation Training
Description: Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
Study: NCT02357563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: 5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
Study: NCT00022542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study: NCT02093130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03499886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride 50Mg/1mL Solution for Injection
Description: In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
Study: NCT02539862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy online
Description: The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
Study: NCT01534286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theramine
Description: Theramine 2 capsules 3 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theramine- like placebo
Description: Theramine-like placebo capsules 2 three times daily
Study: NCT03322124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenidinedihydrochlorid
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
Study: NCT03063866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 1 mg/kg i.v

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 3 mg i.v

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 0.5 ug/kg
Study: NCT02917629

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT02842788

Intervention type: PROCEDURE
Intervention: Prone positioning
Description: Turning the patient face down for several consecutive hours
Study: NCT03063866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 0.5 ug/kg
Study: NCT04758416

Intervention type: PROCEDURE
Intervention: biopsy or surgical pathology in metastases
Description: biopsy or surgical pathology in extrahepatic/liver/brain metastases

Intervention type: DRUG
Intervention: 68Ga-HER2 affibody,18F-FDG, 18F-FES
Description: 68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
Study: NCT01738438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Study: NCT01704196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepicastat
Description: 120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02910713

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intranasal Tear Neurostimulator
Description: The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Tear Neurostimulator
Description: The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
Study: NCT03189472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
Study: NCT01425749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recMAGE-A3 + AS15 ASCI
Description: Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recMAGE-A3 + AS15 ASCI
Description: Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
Study: NCT03044470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Role of cryotherapy in reduction of post operative pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Role of cryotherapy in reduction of post operative pain
Study: NCT03731546

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: Cord clamping 60 seconds after delivery of fetus in preterm infants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: Cord clamping 60 seconds after delivery of fetus in preterm infants
Study: NCT03864536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Prescriptions
Description: Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Prescriptions
Description: Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
Study: NCT02253017

Intervention type: OTHER
Intervention: Children operated on for cataract
Description: Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
Study: NCT01459068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: CETA components include:~1. Engagement (encouraging participation)~2. Psychoeducation (introduction)~3. Anxiety Management Strategies (relaxation)~4. Behavioral Activation (getting active)~5. Cognitive Coping/Restructuring (thinking in a different way, part I and part II)~6. Imaginal Gradual Exposure (talking about difficult memories)~7. In Vivo Exposure (Live exposure)~8. Suicide/Homicide/Danger Assessment and Planning (safety)~9. Screening and Brief Intervention for Alcohol (alcohol intervention)
Study: NCT03067844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab
Description: Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
Study: NCT03339401

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
Study: NCT00638417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Description: maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional rehabilitation
Description: conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (\>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (\>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
Study: NCT04154917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOME
Description: HOME's focus is on the person's functional ability, safety and transition from hospital to home. HOME will be delivered by a community-based clinician (OT who will be involved in the hospital discharge planning) trained by the PI. Training will include two sessions covering assessment of functional ability, goal setting and home safety. The clinician will keep a record of recommendations provided, length of home visit and any adverse events during the intervention. Twice over the course of the study, the PI leader will observe the clinician conducting HOME interventions to assess adherence to the study protocol using a fidelity checklist. The HOME intervention comprises 4 phases, which are described in the arms section.
Study: NCT01972594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targetted protocol with pedometer
Description: 12 week protocol based on targetted steps are given to the patient along with a pedometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer(ActivPAL)
Study: NCT03156855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy
Description: D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
Study: NCT00480831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO95780
Description: Intravenous repeating dose
Study: NCT03156855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth quadruple therapy
Description: D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
Study: NCT02384304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions